Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20215740 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL14946367 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL10459464 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL1937265 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL19981007 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL20459987 | 0.92 | P2RY6 (0.34) | MAPTABL1RIN1POLBROCK2 | |
| SCHEMBL30274755 | 0.88 | ACHE (0.33) | MAPTABL1RIN1POLBNT5E | |
| SCHEMBL16229229 | 0.88 | MAPT (0.31) | MAPTABL1RIN1 | |
| SCHEMBL30274756 | 0.88 | ACHE (0.33) | MAPTABL1RIN1POLBNT5E | |
| SCHEMBL27056650 | 0.88 | ACHE (0.33) | MAPTABL1RIN1POLBNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | MAPT 3587/4885ABL1 1325/4885RIN1 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.